Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Down 86.8% in January

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 8,600 shares, a decline of 86.8% from the January 15th total of 65,100 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Antibe Therapeutics Price Performance

Shares of ATBPF stock remained flat at $0.22 during trading on Thursday. The firm has a 50 day simple moving average of $0.22 and a two-hundred day simple moving average of $0.22. Antibe Therapeutics has a 52 week low of $0.11 and a 52 week high of $0.89. The stock has a market cap of $11.42 million, a PE ratio of -0.86 and a beta of 0.51.

About Antibe Therapeutics

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).